Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | STS | P08842 | 6/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264561 | 1.00 | SOD1 (0.46) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL6250110 | 1.00 | SOD1 (0.46) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL6249723 | 1.00 | SOD1 (0.46) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL6248679 | 1.00 | SOD1 (0.46) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| Bicarbonate SCHEMBL7026810 | 0.75 | SOD1 (0.54) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL7213776 | 0.74 | SHBG (0.55) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL6247117 | 0.71 | ESR1 (0.49) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL15945865 | 0.71 | ESR1 (0.74) | SOD1ESR2ESR1CYP19A1NR3C1 | |
| SCHEMBL6282209 | 0.70 | SOD1 (0.66) | SOD1CYP19A1NR1H2NR1H3 | |
| SCHEMBL31481794 | 0.70 | NR1H2 (0.52) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399406-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I | KAROBIO AB (SE) | 2005-08-10 | — | — | EP | claimed |
| US-20040127576-A1 | Estrogen receptor modulators | KARO BIO AB (SE) | 2004-07-01 | — | — | US | claimed |
| EP-1399406-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I | KAROBIO AB (SE) | 2005-08-10 | — | — | EP | disclosed |
| US-20040127576-A1 | Estrogen receptor modulators | KARO BIO AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127576-A1 | Estrogen receptor modulators | GPER1, ESRRA, ESRRB | SOD1 4581/4885ESR2 4/4885ESR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.